IMMP (Immutep) Cash-to-Debt: N/A (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IMMP Immutep Ltd IMMP
23 GF Score
Price $0.39
! 1 Warning Sign
View Full Analysis

What is Immutep Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Immutep's cash to debt ratio for the quarter that ended in Mar. 2026 was N/A.

The historical rank and industry rank for Immutep's Cash-to-Debt or its related term are showing as below:

IMMP' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.12   Med: 5.63   Max: 114.1
Current: 79.81

During the past 13 years, Immutep's highest Cash to Debt Ratio was 114.10. The lowest was 2.12. And the median was 5.63.

IMMP's Cash-to-Debt is ranked better than
75.52% of 1401 companies
in the Biotechnology industry
Industry Median: 6.43 vs IMMP: 79.81

Immutep  (NAS:IMMP) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Immutep Cash-to-Debt Related Terms

Immutep Cash-to-Debt Historical Data

* Premium members only.

The historical data trend for Immutep's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Immutep Cash-to-Debt Chart

Immutep Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 46.15 100.52 114.15 79.81 N/A

Immutep Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 79.81 N/A 81.92 N/A N/A

IMMP vs VRTX, REGN, RVMD: Cash-to-Debt Comparison

For the Biotechnology subindustry, Immutep's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immutep Cash-to-Debt vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immutep's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Immutep's Cash-to-Debt falls into.


IMMP
23GF Score
Immutep Ltd IMMP
Cash-to-Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immutep Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Immutep's Cash to Debt Ratio for the fiscal year that ended in Jun. 2025 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=84.436 / (0.853 + 0.205)
=79.81

Immutep's Cash to Debt Ratio for the quarter that ended in Mar. 2026 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immutep Business Description

Address 264 George Street, Level 32, Australia Square, Sydney, NSW, AUS, 2000
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
23GF Score

Get the complete analysis for IMMP

Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.39
Price